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Abstract We identified PNKPmutations in a Norwegian wom-
anwithAOA.This patient had the typical findingswith cognitive
dysfunction, peripheral neuropathy, cerebellar dysarthria, hori-
zontal nystagmus, oculomotor apraxia, and severe truncal and
appendicular ataxia. In addition, she had hypoalbuminemia and
massive lower limb edema which showed some improvement
with treatment. Exome sequencing identified two heterozygous
mutations, one in exon 14 (c.1196T>C, p.Leu399Pro) and one in
exon 16 (c.1393_1396del, p.Glu465*). This is the first non-
Portuguese patient with AOA due to PNKP mutations and pro-
vides independent verification that PNKPmutations causeAOA.
Keywords Ataxia . Oculomotor apraxia . Edema .
Hypoalbuminemia . AOA4
Introduction
Ataxia with oculomotor apraxia (AOA) is an autosomal reces-
sive disorder characterized by the combination of progressive
spinocerebellar ataxia, sensory and motor peripheral neurop-
athy, and various extrapyramidal features including
choreoathetosis, dystonia, and tremor.
Four genetically distinct types have been described. AOA1
(MIM#208920) caused by mutations in APTX encoding
aprataxin is characterized by hypoalbuminemia and hypercho-
lesterolemia [1]. AOA2 (MIM#606002) due to mutations in the
SETX gene encoding senataxin commonly shows increased se-
rum alpha-fetoprotein levels [2]. AOA3 (MIM#615217) is
caused by PIK3R5 encoding phosphoinositide-3-kinase, regula-
tory subunit 5 [3]. A fourth type termed AOA4 (MIM#616267)
was described recently in eight Portuguese families carrying
mutations in the PNKP gene encoding polynucleotide kinase
30-phosphatase, a protein involved in DNA-damage repair [4].
AOA4 starts in early childhood and is clinically characterized by
dystonia, ataxia, oculomotor apraxia, sensorimotor peripheral
neuropathy with distal amyotrophy, and cognitive impairment.
Hypoalbuminemia, hypercholesterolemia, and elevated alpha-
fetoprotein have been described in some patients but neither
occurs consistently. The clinical and genetic features of AOA
are summarized in the table.
We have identified the first non-Portuguese patient with
AOA due to PNKP mutations. Our findings confirm the role
of PNKP in causing AOA an independent population.
Case Report
Clinical Description
The patient, a 50-year-old woman of Norwegian ancestry with-
out family history of neurological disease, was referred to our
center due to progressive gait unsteadiness. She was born to
non-consanguineous parents after a normal pregnancy, delivery,
and early psychomotor development. At age 6, she developed
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progressive gait unsteadiness and general motor clumsiness.
From her early twenties, she complained of numbness and re-
duced sensation with a glove and stocking distribution and distal
weakness in the lower limbs. At the age of 30 years, she became
wheel-chair-bound.
Clinical examination at the age of 31 revealed moderate cog-
nitive dysfunction. She had cerebellar dysarthria, horizontal nys-
tagmus, oculomotor apraxia, and severe truncal and appendicu-
lar ataxia with dysmetria and dysdiadochokinesia. She could not
stand or walk unsupported. There was flaccid paralysis at the
ankles, bilateral pes cavus and hammer toe deformities, and
global hypoesthesia in the distal limbs. She had generalized
subcutaneous edema (anasarca), which was most pronounced
in the lower limbs (Fig. 1d).
Nerve conduction velocities (NCVs) and electromyography
(EMG) were technically difficult in the lower limbs due to the
edema. In the upper limbs, there was decreased conduction ve-
locity in the median nerve (distal latency 5.9 ms, conduction
velocity 33 m/s, amplitude 2.9 mV). EMG showed mild dener-
vation activity and increased amplitude of the motor unit poten-
tials. Overall, the results were consistent with combined demy-
elination (slowed conduction velocity and increased distal laten-
cy) and axonal damage (low neurographic amplitudes, denerva-
tion activity, and increased amplitude of the motor unit
potentials). MRI showed cerebellar, pontine, and generalized
cerebral atrophy (Fig. 1a, b)
Blood chemistry showed hypoalbuminemia ranging
from 25 to 30 g/L (normal 39–47 g/L), and elevated total
cholesterol 9.5 mmol/L (normal 3.3–7.7 mmol/L) and
LDL 6.9 mmol/L (normal 1.8–5.7 mmol/L). AFP levels
were within normal range.
Her edema was treated with repeated albumin replacement
therapy and compressive limb therapy (Lymphopress, I-Tech,
Italy) resulting in some improvement (Figs. 1d, e and 2).
Genetics
DNAwas purified from blood using standard methods. Whole-
exome sequencing was performed at HudsonAlpha Institute for
Biotechnology (Huntsville, AL) using Roche-NimbleGen
Sequence Capture EZ Exome v3 kit and paired-end 100 nt se-
quencing on the Illumina HiSeq. Read mapping, variant calling,
and filtering was performed as described previously [5].
PCR-amplification and Sanger sequencing of the
PNKP gene was performed by standard methods (primers
and conditions available upon request). Biallelic muta-
tions were found in 14 genes of which only PNKP was
consistent with the patient’s phenotype (Table 1). The
Fig. 1 Clinical and radiological
features of our patient. a Coronal
FLAIR-T2 MRI showing
generalized cerebral atrophy and
ex vacuo ventricular dilation. b
Sagittal T1-weighted MRI
showing midline cerebellar
atrophy. c Axial T2-weighted
MRI showing cerebellar and
pontine atrophy with dilation of
the fourth ventricle and punctate
bilateral high signal lesions at the
base of the middle cerebellar
peduncles (arrow). d Photograph
of the patient showing severe
bilateral edema of the lower
limbs. e Improvement of the
edema after albumin infusion and
compression treatment
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PNKP gene (NCBI reference sequence NM_007254)
contained two heterozygous mutations, one in exon 14
(c.1196 T > C, p.Leu399Pro) and one in exon 16
(c.1393_1396del, p.Glu465*). Sanger sequencing con-
firmed the mutations and sequencing of the parents
showed that they were located on different alleles. The
c.1196 T >C was absent in 400 in-house controls and
the 1000 genomes database and had an allele frequency
of 6 × 10−4 (no homozygous individuals) at the Exome
Aggregation Consortium (ExAC), Cambridge, MA
(URL: http://exac.broadinstitute.org). It is predicted to
change a highly conserved leucine for proline in
position 399. The c.1393_1396del non-sense mutation
has not been previously reported and was absent in our
controls and public databases. It is predicted to introduce
a stop codon and premature truncation of the protein.
Based on their very low frequency, predicted biological
impact and compatibility with the phenotype, the muta-
tions were considered pathogenic.
Discussion
We report a sporadic case of AOA4 caused by known and
novel mutations of the PNKP gene. This is only the ninth
Fig. 2 Genetic findings. Pedigree
of the family showing the patient
(black circle and arrow) and her
healthy sister and parents.
Chromatograms show the
location of the mutations (arrows)
in each individual
Table 1 Major clinical features of the four AOA subtypes
Disease Gene Ataxia OA PN Extrap* Cogn Alb Chol AFP
AOA1 APTX + + + + +/− + + −
AOA2 SETX + + + + +/− − + +
AOA3 PIK3R5 + + + − − − − +
AOA4 PNKP + + + + + + + +
OA oculomotor apraxia, PN peripheral neuropathy, Extrap extrapyrami-
dal (choreoathetosis, dystonia, tremor), Cogn cognitive decline, Alb hy-
poalbuminemia, Chol hypercholesterolemia, AFP elevated AFP
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reported family and the first independent replication of
PNKP mutations as a cause of AOA in a different
population.
Our patient’s most striking clinical feature was the
severe bilateral oedema of the lower limbs due to hy-
poalbuminemia. Limb edema affects approximately half
the patients with AOA1, but has not been previously
reported in AOA4 [4, 6]. Otherwise, the patient had
typical clinical features for this disorder including pe-
ripheral neuropathy, cognitive impairment, and hyper-
cholesterolemia, but no extrapyramidal dysfunction
which was present in the majority of the reported pa-
tients (9/11) [4].
In conclusion, our findings confirm the pathogenic role
of PNKP in an independent, novel case of AOA4.
Moreover, we show that PNKP mutations should be con-
sidered in the differential diagnosis of recessive and/or
sporadic ataxia also in non-Portuguese populations.
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